98%
921
2 minutes
20
The laborious annotation process and inherent image ambiguity exacerbate difficulties of data acquisition for medical image segmentation, leading to suboptimal performance in practice. This paper proposes a workaround against these challenges aiming to learn unbiased models solely from certainties. Concretely, during the labeling stage, only regions of interest confidently discerned by annotators are required to be labeled, not only increasing label quantity but also improving label quality. This approach formulates the positive-unlabeled (PU) segmentation problem and motivates to capture uncertainty in ambiguous regions. We thus delve into data-generating assumptions in the PU segmentation context and propose Probabilistic PU Segmentation Networks (ProPU-Nets) to tackle problems abovementioned. This framework employs the expectation-maximization algorithm to gradually estimate true masks, and more importantly, by encoding plausible segmentation variants in a latent space, uncertainty estimation can be naturally embedded into the PU segmentation framework. Benefitting from the framework's unbiasedness, a semi-supervised PU segmentation method is also proposed, which can further excavate performance gains from unlabeled data. We conduct extensive experiments on LIDC, RIGA, and LA datasets, and comprehensively compared with state-of-the-art methods in label-efficient medical image segmentation. The results justify the method's effectiveness and practical prospect.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.media.2025.103745 | DOI Listing |
Adv Ther
September 2025
Bristol Myers Squibb, Princeton, NJ, 08540, USA.
Background And Objectives: Deucravacitinib, a first-in-class, oral, selective, allosteric tyrosine kinase 2 inhibitor, demonstrated efficacy across the primary endpoint and all key secondary endpoints in the phase 2 PAISLEY SLE trial in patients with active systemic lupus erythematosus (SLE). Here, we describe 2 phase 3 trials [POETYK SLE-1 (NCT05617677), POETYK SLE-2 (NCT05620407)] which will assess the efficacy and safety of deucravacitinib in patients with active SLE. These phase 3 trials have been designed to replicate the successful elements of the phase 2 trial, including its glucocorticoid-tapering strategy and disease activity adjudication.
View Article and Find Full Text PDFJpn J Ophthalmol
September 2025
Department of Medical Education Studies, International Research Center for Medical Education, Graduate School of Medicine, The University of Tokyo, Bunkyō, Tokyo, Japan.
Purpose: To examine the associations between work-family conflict, implicit gender bias, and turnover intention among hospital ophthalmologists.
Study Design: Cross-sectional study.
Methods: We conducted a web-based questionnaire survey between January and February 2024.
Diabetes Ther
September 2025
Department of Diabetes and Endocrinology, Guy's and St Thomas' NHS Trust, London, UK.
Introduction: This post hoc analysis of an A Toujeo Observational Study (ATOS) aims to evaluate the real-world effectiveness and safety of insulin glargine 300 U/ml (Gla-300) in high-risk subgroups of insulin-naïve people with type 2 diabetes (PwT2D) from multiple geographical regions (Asia, the Middle East, North Africa, Latin America, and Eastern Europe).
Methods: In these post hoc analyses of ATOS, a real-world, 12-month, prospective study included 4422 insulin-naïve adults (age ≥ 18 years) with type 2 diabetes (T2D) uncontrolled (HbA > 7% and ≤ 11%) on one or more oral antidiabetic drugs (OADs) who initiated Gla-300 treatment as per routine practice. Primary and secondary endpoints were studied according to renal impairment (RI) status (without or with) and age group (≥ 70 years).
Environ Monit Assess
September 2025
Department of Geography, Rampurhat College, University of North Bengal, Darjeeling, 734013, India.
Catastrophic climate events such as floods significantly impact infrastructure, agriculture, and the economy. The lower Gandak River basin in India is particularly flood-prone, with Bihar experiencing annual losses of life and property due to massive flooding. Identifying flood-prone zones in this region is essential.
View Article and Find Full Text PDFHead Neck Pathol
September 2025
Department of Laboratory Medicine and Pathology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, USA.
Myoepithelial carcinoma (MECA) is a malignant neoplasm composed exclusively of myoepithelial cells and accounts for less than 1% of all salivary gland tumors. Its diagnosis is often challenging due to histologic overlaps with benign lesions and its variable morphologic presentation. Although molecular profiling has emerged as a valuable tool in salivary gland tumor classification, the genetic landscape of MECA remains incompletely defined.
View Article and Find Full Text PDF